Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine progression-free survival of lung cancer patients who received gefitinib in clinical practice in Thailand.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Progression-free survival | median time from the first date of treatment until date of disease progression during Jan 2004- Dec 2008 or 5 years approx. |
| Measure | Description | Time Frame |
|---|---|---|
| Time to maximum response | Median time from the first date of treatment until the date that the disease can be maximum controlled during Jan 2004- Dec 2008 or 5 years approx. | |
| Overall survival | time from the first date of treatment until date of patients dead during Jan 2004- Dec 2008 or 5 years approx. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Lung cancer patients admitted in Chulalongkorn and Siriraj hospitals between January 2004 and December 2008 and treated with gefitinib for at least 3 months
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Virote Sriuranpong, MD., PhD. | Chulalongkorn Hospital, Bangkok, Thailand | Principal Investigator |
| Vichien Srimuninnimit, MD. | Siriraj Hospital, Bangkok, Thailand | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Bangkok | Thailand |
Not provided
| ID | Term |
|---|---|
| D008175 | Lung Neoplasms |
| ID | Term |
|---|---|
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Tissue
| Prevalence of EGFR & KRAS mutation from laboratory result | During Jan 2004- Dec 2008 or 5 years approx. |
| D008171 |
| Lung Diseases |
| D012140 | Respiratory Tract Diseases |